Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 4/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.46 |
| ▸ | ALKBH1 | Q13686 | 6/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24945650 | 1.00 | PRMT5 (0.53) | PRMT5KITGHSRALKBH1P4HTM | |
| SCHEMBL20046584 | 0.81 | TDP1 (0.47) | PRMT5ALKBH1CREBBP | |
| Hydrochloric Acid SCHEMBL29614025 | 0.81 | SLC6A4 (0.45) | KITALKBH1P4HTM | |
| SCHEMBL26077251 | 0.79 | KIT (0.53) | KITALKBH1P4HTMGPR119SLC6A7 | |
| SCHEMBL15952657 | 0.78 | KIT (0.54) | KITALKBH1P4HTMGPR119SLC6A7 | |
| SCHEMBL26077257 | 0.77 | KDM4E (0.47) | KITALKBH1 | |
| SCHEMBL29614210 | 0.77 | ALKBH1 (0.45) | KITALKBH1P4HTMGPR119GRM2 | |
| SCHEMBL8106889 | 0.77 | TAAR1 (0.67) | PRMT5KITALKBH1SLC6A7 | |
| SCHEMBL23730789 | 0.77 | KIT (0.44) | PRMT5KITALKBH1P4HTMGPR119 | |
| SCHEMBL24944807 | 0.77 | P4HTM (0.50) | KITALKBH1P4HTMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258336-B2 | Preparation of seimicarbazide-sensitive amine oxidase inhibitor and use thereof | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2025-03-25 | — | — | US | disclosed |
| CN-112839940-B | Preparation and application of semicarbazide-sensitive amine oxidase inhibitor | 上海轶诺药业有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20220081426-A1 | PREPARATION OF SEIMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITOR AND USE THEREOF | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3858827-A1 | PREPARATION OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITOR AND USE THEREOF | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858827-A1 | PREPARATION OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITOR AND USE THEREOF | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081426-A1 | PREPARATION OF SEIMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITOR AND USE THEREOF | MAOB, MAOA, SMOX | PRMT5 650/4885KIT 322/4885GHSR 1937/4885 |
| US-12258336-B2 | Preparation of seimicarbazide-sensitive amine oxidase inhibitor and use thereof | MAOB, MAOA, SMOX | PRMT5 650/4885KIT 322/4885GHSR 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.